Frontline Treatment Selection in Metastatic Pancreatic Cancer
Midhun Malla, MD
Michael A. Morse, MD, FACP, MHS
Benjamin Leon Musher, MD
Janie Y. Zhang, MD
Rahul Gosain, MD, MBA
Rohit Gosain, MD
Key Points
- Modified FOLFIRINOX (5-fluorouracil [5-FU]/leucovorin, irinotecan, and oxaliplatin), NALIRIFOX (liposomal irinotecan, 5-FU/leucovorin, and oxaliplatin), and gemcitabine plus nab-paclitaxel remain the primary frontline treatment options for metastatic pancreatic adenocarcinoma.
- NAPOLI 3 demonstrated improved overall survival (OS) with NALIRIFOX compared with gemcitabine plus nab-paclitaxel.
- Performance status and functional assessment are critical determinants of treatment selection.
- Treatment discussions should incorporate patient goals, quality of life (QOL) considerations, and molecular profiling results.
At a Clinical Insights discussion coinciding with the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Brothers podcast cohosts Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, welcomed panelists Midhun Malla, MD, of the University of Alabama; Michael A. Morse, MD, FACP, MHS, of Duke Cancer Center; Benjamin Leon Musher, MD, of Baylor College of Medicine; and Janie Y. Zhang, MD, of the University of Pittsburgh, to review the evolving frontline management of metastatic pancreatic adenocarcinoma.
The panel emphasized that despite recent advances, systemic chemotherapy remains the foundation of treatment, with therapeutic decisions balancing efficacy, toxicity, and QOL in a disease that remains associated with poor outcomes.
Dr. Malla outlined the current frontline treatment landscape, highlighting modified FOLFIRINOX, NALIRIFOX, and gemcitabine plus nab-paclitaxel as the primary evidence-based options. He reviewed the regimens’ historical development, beginning with the PRODIGE trial that established FOLFIRINOX as a superior alternative to single-agent gemcitabine and the MPACT trial that demonstrated improved survival with gemcitabine plus nab-paclitaxel. More recently, the phase 3 NAPOLI 3 study showed improved OS with NALIRIFOX compared with gemcitabine plus nab-paclitaxel, further expanding first-line treatment options.
Dr. Morse then discussed the clinical implications of NAPOLI 3, noting that NALIRIFOX achieved a median OS of 11.1 months compared with 9.2 months for gemcitabine plus nab-paclitaxel. He emphasized that treatment selection extends beyond efficacy data. Performance status remains the most critical factor guiding regimen choice, and clinicians should carefully evaluate functional independence, comorbidities, and social support systems. Informal geriatric assessments often provide valuable insights into a patient’s ability to tolerate intensive therapy.
The panel stressed the importance of aligning treatment recommendations with patient goals. Because metastatic pancreatic cancer remains incurable, discussions should focus on realistic expectations regarding symptom control, QOL, and meaningful life events that patients hope to experience. Molecular profiling may further refine treatment decisions, particularly for patients harboring BRCA or other homologous recombination repair alterations, who may derive additional benefit from platinum-based strategies.